10-Q quarterly report · filed Nov 12, 2026

DiaMedica Therapeutics Inc. (DMAC) Q3 2026 10-Q Quarterly Report

Short answer

DiaMedica Therapeutics Inc. (DMAC) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$11M
−31.2% YoY · −11.5% QoQ
EPS (diluted)
−$0.20
−17.6% YoY · −5.3% QoQ

Source: XBRL data from the DiaMedica Therapeutics Inc. (DMAC) Q3 2026 10-Q on SEC EDGAR. USD.

DiaMedica Therapeutics Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, with no product sales
  • R&D expenses $9.2M vs $6.4M YoY, G&A expenses $2.4M vs $2.6M
  • Net loss $31.5M for nine months vs $24.0M YoY, no margin figures disclosed
  • Cash, equivalents and securities $34.9M vs $59.9M at December 31, 2025
  • ReMEDy2 enrollment slower than expected, interim results expected by end of Q1 2027; additional funding anticipated

Risk Factors

  • No material changes to previously disclosed risk factors in the December 31, 2025 Form 10-K
  • Carried-forward risk: unknown or currently immaterial risks could impair business, financial condition, or results of operations
  • Carried-forward disclosure: existing uncertainties could cause actual results to differ materially from forward-looking statements

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other DiaMedica Therapeutics Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.